What is the ethical responsibility of a provider when prescribing the new direct‐acting antiviral agents to patients with hepatitis C infection?

Publisher： John Wiley & Sons Inc

E-ISSN： 2046-2484|6|5|117-119

ISSN： 2046-2484

Source： CLINICAL LIVER DISEASE (ELECTRONIC), Vol.6, Iss.5, 2015-11, pp. : 117-119

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Access to new direct‐acting antiviral agents against HCV infection: A view from Spain

By  

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 5, Iss. 1, 2015-01 ,pp. : 22-23

John Wiley & Sons Inc

Access to resources Recommend Favorite

The new treatments for hepatitis C virus: An advanced practice provider's perspective

By  

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 4, Iss. 6, 2014-12 ,pp. : 153-155

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is it ethical to enroll a patient in a hepatitis C virus clinical trial when current standard of care is highly effective and safe?

By  

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 6, Iss. 5, 2015-11 ,pp. : 120-121

John Wiley & Sons Inc

Access to resources Recommend Favorite

What Is the ethical (Not Legal) responsibility of a physician to treat minimal hepatic encephalopathy and advise patients not to drive?

By  

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 6, Iss. 4, 2015-10 ,pp. : 86-89

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dynamics of Hepatitis B Virus Infection: What Causes Viral Clearance?

By CIUPE STANCA   CATLLA ANNE   FORDE JONATHAN   SCHAEFFER DAVID  

Mathematical Population Studies, Vol. 18, Iss. 2, 2011-04 ,pp. : 87-105

Routledge Ltd

Access to resources Recommend Favorite